Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer. 2013 Sep 22;13. 429.

Auvinen A, Seppä K, Pasanen K, Kurttio P, Patama T, Pukkala E et al. Chernobyl fallout and cancer incidence in Finland 1988-2007. International Journal of Cancer. 2014 May 1;134(9):2253-2263.

Azaïs H, Moussaron A, Bach SK, Bassil A, Betrouni N, Frochot C et al. FRα: une cible pour la thérapie photodynamique prophylactique des métastases péritonéales ovariennes? BULLETIN DU CANCER. 2014 Dec 1;101(12):1109-1113.

Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T et al. Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis. BMC Cancer. 2013 Mar 1;13. 96.

Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B et al. Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer. 2012 Feb 14;106(4):768-774.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A. RE: Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2014 May 14;106(5). dju079.

Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X et al. Thérapie photodynamique et carcinomes urothéliaux. BULLETIN DU CANCER. 2011 Jul;98(7):769-778.

Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS et al. Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. International Journal of Cancer. 2011 Nov 15;129(10):2400-2407.

Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFκB dependent manner. Cancer Letters. 2013 Aug 19;336(2):347-358.

Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. CELL DEATH AND DISEASE. 2012 Feb;3(2). e271.

Egerdie RB, Saad F, Smith MR, Tammela TLJ, Heracek J, Sieber P et al. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2012 Sep;15(3):308-312.

Elme A, Utriainen M, Kellokumpu-Lehtinen P, Palva T, Luoto R, Nikander R et al. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. Anticancer Research. 2013 Apr;33(4):1595-1602.

Emmert-Streib F, Zhang SD, Hamilton P. Computational cancer biology: education is a natural key to many locks. BMC Cancer. 2015 Jan 15;15(1). 7.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B et al. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. EUROPEAN JOURNAL OF CANCER. 2014;50(9):1617-1627.

Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schüz J. European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. CANCER EPIDEMIOLOGY. 2015 Dec 1;39:S107-S119.

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvuori P et al. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro-Oncology. 2017 Sep 1;19(9):1206-1216.

Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A et al. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. CANCER EPIDEMIOLOGY. 2015 Dec 1;39:S75-S83.

Haillot O, Fraga A, MacIukiewicz P, Pushkar D, Tammela T, Höfner K et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. PROSTATE CANCER AND PROSTATIC DISEASES. 2011 Dec;14(4):302-306.

Heijnsdijk EAM, De Carvalho TMD, Auvinen A, Zappa M, Nelen V, Kwiatkowski M et al. Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015 Jan 1;107(1). dju366.

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. Anticancer Research. 2012 Aug;32(8):3305-3310.

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL. Effects of single and fractionated irradiation on natural killer cell populations: Radiobiological characteristics of viability and cytotoxicity in vitro. Anticancer Research. 2015 Oct 1;35(10):5193-5200.

Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A et al. Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. Carcinogenesis. 2013 Sep;34(9):2000-2009.

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H et al. Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. Oncogene. 2012 Aug 2;31(31):3597-3606.

Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP et al. Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis. PLOS GENETICS. 2012 Aug;8(8). e1002907.

Jayakrishnan R, Uutela A, Mathew A, Auvinen A, Mathew PS, Sebastian P. Smoking cessation intervention in Rural Kerala, India: Findings of a randomised controlled trial. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(11):6797-6802.

Jayakrishnan R, Mathew A, Uutela A, Auvinen A, Sebastian P. Multiple approaches and participation rate for a community based smoking cessation intervention trial in rural Kerala, India. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(5):2891-2896.

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R et al. Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. JOURNAL OF CLINICAL ONCOLOGY. 2012 Jan 1;30(1):11-18.

Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. International Journal of Cancer. 2015 Sep 1;137(5):1187-1195.

Kapanen M, Laaksomaa M, Tulijoki T, Kellokumpu-Lehtinen PL, Hyödynmaa S. Effects of remedies made in patient setup process on residual setup errors and margins in head and neck cancer radiotherapy based on 2D image guidance. Reports of Practical Oncology and Radiotherapy. 2015 Jul 1;20(4):292-298.

Kellokumpu-Lehtinen PL, Tuunanen T, Kautio AL, Lehtinen I, Tanner M. Bi-weekly paclitaxel and capecitabine as a second- Or third-line treatment for advanced breast cancer: A pilot study. Anticancer Research. 2013 Nov;33(11):4941-4945.

Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R et al. Weekly paclitaxel-An effective treatment for advanced breast cancer. Anticancer Research. 2013 Jun;33(6):2623-2628.

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T et al. Toxicity in patients receiving adjuvant docetaxel hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. PROSTATE CANCER AND PROSTATIC DISEASES. 2012 Sep;15(3):303-307.

Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study. Cancer Causes and Control. 2011 Oct;22(10):1445-1452.

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Research. 2013 Nov 15;73(22):6757-6769.

Kilpeläinen TP, Tammela TLJ, Malila N, Hakama M, Santti H, Määttänen L et al. The Finnish prostate cancer screening trial: Analyses on the screening failures. International Journal of Cancer. 2015 May 15;136(10):2437-2443.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L et al. Prostate cancer mortality in the finnish randomized screening trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 May 15;105(10):719-725.

Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V et al. False-positive screening results in the European randomized study of screening for prostate cancer. EUROPEAN JOURNAL OF CANCER. 2011 Dec;47(18):2698-2705.

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J et al. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 2020;39:5241–5251.

Koskinen MJ, Kautio AL, Haanpää ML, Haapasalo HK, Kellokumpu-Lehtinen PL, Saarto T et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Research. 2011 Dec;31(12):4413-4416.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K et al. Hypermethylation of the GABRẼmiR-452̃miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clinical Cancer Research. 2014 Apr 15;20(8):2169-2181.

Kuittinen T, Rovio P, Luukkaala T, Laurila M, Grénman S, Kallioniemi A et al. Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian cancer cells in vitro. Anticancer Research. 2020 Jun 1;40(6):3129-3138.

Kurttio P, Seppä K, Pasanen K, Patama T, Auvinen A, Pukkala E et al. Fallout from the Chernobyl accident and overall cancer incidence in Finland. CANCER EPIDEMIOLOGY. 2013 Oct;37(5):585-592.

Kuusela J, Kim J, Räsänen E, Aalto-Setälä K. The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes. Stem Cell Reviews and Reports. 2016;12(6):698–707.

Laaksomaa M, Kapanen M, Skyttä T, Peltola S, Hyödynmaa S, Kellokumpu-Lehtinen PL. Estimation of optimal matching position for orthogonal kV setup images and minimal setup margins in radiotherapy of whole breast and lymph node areas. Reports of Practical Oncology and Radiotherapy. 2014 Nov 1;19(6):369-375.

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TLJ, Wahlfors T et al. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. International Journal of Cancer. 2015 May 15;136(10):2316-2327.

Larjavaara S, Feychting M, Sankila R, Johansen C, Klaeboe L, Schüz J et al. Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987-2007. British Journal of Cancer. 2011 Sep 27;105(7):1069-1075.

Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene. 2011 Feb 17;30(7):790-805.

Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes and Cancer. 2013 Dec;52(12):1103-1113.

Lehti M, Valkeinen H, Sipilä S, Perhonen M, Rottensteiner M, Pullinen T et al. Effects of aerobic and strength training on aerobic capacity, muscle strength, and gene expression of lymphomonocytes in patients with stable CAD. American Journal of Translational Research. 2020;12(8):4582-4593.

Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli-Harja O et al. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 2017 May 3;17(1). 310.

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research. 2011 Mar 15;71(6):2108-2117.

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013 Jul 1;119(13):2405-2412.

Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2012 Aug 30;31(35):3939-3948.

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 Jul 3;105(13):960-967.

Mäenpa J, Puistola U, Riska H, Sintonen H, Saarni O, Juvonen E et al. Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: A prospective observational study using the generic 15D instrument. Anticancer Research. 2014 May 1;34(5):2325-2330.

Manzini S, Viiri LE, Marttila S, Aalto-Setälä K. A Comparative View on Easy to Deploy non-Integrating Methods for Patient-Specific iPSC Production. Stem Cell Reviews and Reports. 2015 Dec 1;11(6):900-908.

Martens-Uzunova ES, Jalava SE, Dits NF, Van Leenders GJLH, Møller S, Trapman J et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012 Feb 23;31(8):978-991.

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H et al. NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. BMC Cancer. 2011 Aug 2;11. 327.

McColl N, Auvinen A, Kesminiene A, Espina C, Erdmann F, de Vries E et al. European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. CANCER EPIDEMIOLOGY. 2015 Dec 1;39:S93-S100.

Nissinen SI, Roine A, Hokkinen L, Karjalainen M, Venäläinen M, Helminen H et al. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis. Anticancer Research. 2019 Jan;39(1):73-79.

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S et al. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. International Journal of Cancer. 2019.

Nurminen R, Lehtonen R, Auvinen A, Tammela TLJ, Wahlfors T, Schleutker J. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death. EUROPEAN JOURNAL OF CANCER. 2013 Oct;49(15):3335-3343.

Nurminen R, Wahlfors T, Tammela TLJ, Schleutker J. Identification of an aggressive prostate cancer predisposing variant at 11q13. International Journal of Cancer. 2011 Aug 1;129(3):599-606.

Pashayan N, Pharoah PDP, Schleutker J, Talala K, Tammela TLJ, Määttänen L et al. Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC. British Journal of Cancer. 2015 Sep 29;113(7):1086-1093.

Penttinen H, Rautalin M, Roine R, Jahkola T, Kellokumpu-Lehtinen PL, Huovinen R et al. Quality of life of recently treated patients with breast cancer. Anticancer Research. 2014 Mar 1;34(3):1201-1206.

Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnersjö A et al. Cancer incidence among Nordic airline cabin crew. International Journal of Cancer. 2012 Dec 15;131(12):2886-2897.

Rahu K, Hakulinen T, Smailyte G, Stengrevics A, Auvinen A, Inskip PD et al. Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986-2007. EUROPEAN JOURNAL OF CANCER. 2013 Sep;49(13):2926-2933.

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT et al. Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. British Journal of Cancer. 2015 Aug 11;113(4):611-615.

Rantanen T, Kauttu T, Åkerla J, Honkanen T, Krogerus L, Salo J et al. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. MEDICAL ONCOLOGY. 2013;30(3). 684.

Rauhala HE, Teppo S, Niemelä S, Kallioniemi A. Silencing of the arp2/3 complex disturbs pancreatic cancer cell migration. Anticancer Research. 2013 Jan;33(1):45-52.

Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J et al. Family history in the finnish prostate cancer screening trial. International Journal of Cancer. 2015 May 1;136(9):2172-2177.

Saarto T, Penttinen HM, Sievänen H, Kellokumpu-Lehtinen PL, Hakamies-Blomqvist L, Nikander R et al. Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors. Anticancer Research. 2012 Sep;32(9):3875-3884.

Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. CELL DEATH AND DISEASE. 2015 May 1;6(5). e1752.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ et al. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research. 2014 Jan 1;74(1):272-286.

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S et al. European code against cancer 4th edition: 12 ways to reduce your cancer risk. CANCER EPIDEMIOLOGY. 2015 Apr 9;39:S1-S10.

Schüz J, Elliott P, Auvinen A, Kromhout H, Poulsen AH, Johansen C et al. An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment. CANCER EPIDEMIOLOGY. 2011 Feb;35(1):37-43.

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J et al. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. EPIGENETICS. 2011;6(10):1248-1256.

Skyttä T, Tuohinen S, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer. Anticancer Research. 2015 Mar 1;35(3):1559-1566.

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Sep 10;30(26):3271-3276.

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J et al. Human breast cancer cells educate macrophages toward the M2 activation status. BREAST CANCER RESEARCH. 2015 Aug 5;17(1). 101.

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TLJ et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. EUROPEAN JOURNAL OF CANCER. 2015 May 30;51(10):1283-1292.

Traylor M, Mäkelä KM, Kilarski LL, Holliday EG, Devan WJ, Nalls MA et al. A Novel MMP12 Locus Is Associated with Large Artery Atherosclerotic Stroke Using a Genome-Wide Age-at-Onset Informed Approach. PLOS GENETICS. 2014;10(7). e1004469.

Tuohinen SS, Skyttä T, Virtanen V, Luukkaala T, Kellokumpu-Lehtinen PL, Raatikainen P. Early effects of adjuvant breast cancer radiotherapy on right ventricular systolic and diastolic function. Anticancer Research. 2015 Apr 1;35(4):2141-2147.

Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM et al. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ngml-1, normal DRE and negative for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2015 Sep 14;18(3):264-269.

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL et al. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer. 2014;111(7):1421-1431.

Veitonmäki T, Tammela TLJ, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. EUROPEAN JOURNAL OF CANCER. 2013 Mar;49(4):938-945.

Venäläinen MK, Roine AN, Häkkinen MR, Vepsäläinen JJ, Kumpulainen PS, Kiviniemi MS et al. Altered polyamine profiles in colorectal cancer. Anticancer Research. 2018 Jun 1;38(6):3601-3607.

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes and Cancer. 2015 May 1;54(5):276-287.

Vihinen PP, Ramadan S, Vuoristo MS, Hernberg M, Tyynelä-Korhonen K, Skyttä T et al. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. MELANOMA RESEARCH. 2011 Oct;21(5):431-437.

Virman JP, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL. VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Research. 2015 Feb 1;35(2):921-927.

Virman JP, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K et al. Claudins as prognostic factors for renal cell cancer. Anticancer Research. 2014 Aug 1;34(8):4181-4188.

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A. Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer. 2018 Mar 27;18(1). 325.

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL. The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. Molecular Imaging and Biology. 2017;19(5):787–794.

Wu GHM, Auvinen A, Määttänen L, Tammela TLJ, Stenman UH, Hakama M et al. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer. 2012 Sep 15;131(6):1367-1375.

Ylipää A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M et al. Transcriptome sequencing reveals PCAT5 as a Novel ERG-Regulated long Noncoding RNA in prostate cancer. Cancer Research. 2015 Oct 1;75(19):4026-4031.

Zoni E, Van Der Horst G, Van De Merbel AF, Chen L, Rane JK, Pelger RCM et al. MIR-25 modulates invasivenessand dissemination of human prostate cancer cells via regulation of αv-and α6-integrin expression. Cancer Research. 2015 Jun 1;75(11):2326-2336.